Minireview: PRKAR1A: normal and abnormal functions

Ioannis Bossis1, Constantine A Stratakis

  • 1Section on Endocrinology and Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1862, USA.

Endocrinology
|August 28, 2004
PubMed

Insights

The PRKAR1A gene, encoding the RIalpha subunit of cAMP-dependent protein kinase (PKA), is linked to Carney complex due to inactivating mutations. While implicated in tumorigenesis, its role as a classic tumor suppressor gene is questioned.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • The RIalpha subunit (PRKAR1A) is central to cAMP-dependent protein kinase (PKA) holoenzyme activity.
  • Carney complex (CNC) is a neoplasia syndrome caused by PRKAR1A-inactivating mutations.
  • RIalpha and PRKAR1A mRNA are upregulated in various neoplasms, suggesting roles in tumorigenesis.

Purpose of the Study:

  • To explore the multifaceted role of PRKAR1A in tumorigenesis.
  • To investigate whether PRKAR1A functions as a classic tumor suppressor gene.

Main Methods:

  • Review of existing literature on PRKAR1A, PKA, and Carney complex.
  • Analysis of gene expression data and mutation studies related to PRKAR1A in neoplasms.

Main Results:

  • PRKAR1A mutations cause Carney complex, indicating a tumor suppressor role in specific contexts.
  • Upregulation of RIalpha and PRKAR1A mRNA in neoplasms suggests broader involvement in cancer.
  • PKA activity alterations have diverse effects based on cellular context.

Conclusions:

  • PRKAR1A's role in tumorigenesis is complex, potentially involving both tumor suppression and oncogenic functions.
  • PRKAR1A likely does not fit the definition of a classic tumor suppressor gene.
  • Further research is needed to elucidate the non-canonical functions of RIalpha and PRKAR1A.